Drug Trial Radar · NCT02547818
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Nov 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
620
Actual
Start
Sep 15, 2015
Primary completion
Nov 13, 2020
Study completion Nov 18, 2020
Sponsor
- Lead sponsor
- AZTherapies, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- PharmaConsulting Group; KCAS Bio; APCER Life Sciences
- First posted
- Sep 11, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subjects with evidence of early stage Alzheimer's disease (AD).
Conditions
- Alzheimer's Disease
Interventions
ALZT-OP1aDrug
1\) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
ALZT-OP1bDrug
Anti-inflammatory
Placebo ALZT-OP1aOther
Non-active capsules
Placebo ALZT-OP1bOther
Non-active tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Dementia Rating-Sum of Boxes (CDR-SB)Time frame: Baseline and Week 72
Locations
121 sites in 7 countries. Site status is shown where the registry gives one.
Cognitive Clinical Trials
Gilbert, Arizona
Xenoscience
Phoenix, Arizona
Cognitive Clinical Trials
Scottsdale, Arizona
Territory Neurology & Research Institute
Tucson, Arizona
Alliance Research Center
Laguna Hills, California
Renew Behavioral Health
Long Beach, California
Excell Research, Inc.
Oceanside, California
University of California Irvine School of Medicine
Orange, California
Asclepes Research Center
Panorama City, California
Artemis Clinical Research
Riverside, California
CITrials
Riverside, California
Northern California Research
Sacramento, California
Syrentys Clinical Research
Santa Ana, California
Mile High Research Center
Denver, Colorado
TOPAZ Clinical Research
Apopka, Florida
Parkinson's Disease & Movement Disorders Center of Boca Raton
Boca Raton, Florida
Bradenton Research Center
Bradenton, Florida
Finlay Medical Research Group
Greenacres City, Florida
Galiz Clinical Research
Hialeah, Florida
The Neurology Research Group
Miami, Florida
Premier Clinical Research Institute
Miami, Florida
Finlay Medical Research Group
Miami, Florida
Next Phase Research Alliance - Cano Health
Miami, Florida
IMIC, Inc.
Miami, Florida
Next Phase Research Alliance - MetroMed
Miami, Florida
Next Phase Research Alliance
Miami, Florida
Panax
Miami Lakes, Florida
CNS Healthcare
Orlando, Florida
Pines Care Research Center
Pembroke Pines, Florida
Neurostudies, Inc.
Port Charlotte, Florida
Progressive Medical Research
Port Orange, Florida
Axiom Clinical Research
Tampa, Florida
Stedman Clinical Trials
Tampa, Florida
Columbus Research & Wellness Institute
Columbus, Georgia
Behavioral Health Care Associates
Schaumburg, Illinois
Eastern Maine Medical Center
Bangor, Maine
Coastal Health Care
Freeport, Maine
Samuel and Alexia Bratton Memory Clinic
Easton, Maryland
ActivMed Practices & Research, Inc.
Methuen, Massachusetts
The Alzheimer's Disease Center
Quincy, Massachusetts
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.